NCT02646748 - Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Biotech Hunter

Enrollment

159

Participants

Timeline

Start Date

January 25, 2016

Primary Completion Date

November 7, 2019

Study Completion Date

November 20, 2020

Conditions

Colorectal Cancer (CRC)Endometrial CancerMelanomaHead and Neck CancerLung CancerMMR-deficient TumorsBreast CancerPancreatic CancerRenal Cell Carcinoma (RCC)Solid TumorsUC (Urothelial Cancer)

Interventions

DRUG

Pembrolizumab

Pembrolizumab 200 mg IV Q3W.

DRUG

itacitinib

Itacitinib tablets administered orally once daily.

DRUG

INCB050465

INCB050465 tablets administered orally once daily.

Trial Locations (17)

10016

NYU Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York

15232

UPMC CancerCenters, Hilman Cancer Center, Pittsburgh

20007

Georgetown University Medical Center Lombardi CCC, Washington D.C.

20817

The Center for Cancer and Blood Disorders (RCCA MD LLC-Maryland Vidision), Bethesda

27710

Duke Cancer Institute, Durham

30322

Emory University, Winship Cancer Institute, Atlanta

37952

Hematology-Oncology Associates of Treasure Coast, Port Saint Lucie

40536

University of Kentucky, Markey Cancer Center, Lexington

48201

Karmanos Cancer Center, Detroit

48202

Henry Ford Hospital System, Detroit

64111

St. Luke's Hospital of Kansas City, Kansas City

75701

HOPE Cancer Center of East Texas, Tyler

84106

Utah Cancer Specialists, Salt Lake City

90404

John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica

94143

University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco

02215

Beth Israel Medical Deaconess Medical Center, Boston

Dana Farber Cancer institute, Boston